Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12283739 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL17581833 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL13436631 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL14012280 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL23998665 | 0.97 | CTSS (0.51) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL23106074 | 0.92 | CTSK (0.50) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL29593613 | 0.91 | CTSK (0.53) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL25459969 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL17209941 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL28342732 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233698-A1 | TREATMENT OF DISEASES CHARACTERIZED BY OVEREXPRESSION OF ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR RECEPTOR A2 (EPHA2) | BICYCLETX LIMITED (GB) | 2023-07-27 | — | — | US | disclosed |
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | BICYCLETX LIMITED (GB) | 2023-07-11 | — | — | US | disclosed |
| US-20220184222-A1 | BICYCLE TOXIN CONJUGATES AND USES THEREOF | BICYCLETX LTD (GB) | 2022-06-16 | — | — | US | disclosed |
| US-20220162308-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-26 | — | — | US | disclosed |
| US-20210228731-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2016109802-A1 | SITE-SPECIFIC CONJUGATION THROUGH GLYCOPROTEINS LINKAGE AND METHOD THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184222-A1 | BICYCLE TOXIN CONJUGATES AND USES THEREOF | EPHA2, EPHB2, EPHB3 | CTSS 1850/4885CTSK 958/4885MEN1 3631/4885 |
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | EPHA2, EPHB2, ERBB2 | CTSS 4373/4885CTSK 3727/4885MEN1 3872/4885 |
| US-20210228731-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | BCR, ABL1, CD47 | CTSS 2889/4885CTSK 1768/4885MEN1 2274/4885 |
| US-20220162308-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | ITGB8, ITGA8, CD4 | CTSS 1310/4885CTSK 1261/4885MEN1 1844/4885 |
| US-20230233698-A1 | TREATMENT OF DISEASES CHARACTERIZED BY OVEREXPRESSION OF ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR RECEPTOR A2 (EPHA2) | EPHA2, EPOR, EPHB2 | CTSS 3432/4885CTSK 2341/4885MEN1 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.